Nestlé says its nutrition therapy biz could be worth $10B; Sanders campaign rejects Shkreli donation;

@FierceBiotech: FierceBiotech Radio on Lilly's latest pipeline peril, Mylan's M&A broken record, and German Merck's big rebrand. More | Follow @FierceBiotech

@JohnCFierce: Zafgen hammered (again) as FDA clamps partial hold on PhIII obesity drug. Report | Follow @JohnCFierce

@DamianFierce: Lost in all this is that "Theranos" would have been a great name for a black metal band. | Follow @DamianFierce

> Nestlé believes its nascent nutritional therapy business, meant to bridge the gap between food and pharma, can eventually grow into a $10 billion enterprise. News

> Hong Kong's Hutchison China MediTech is plotting a $100 million IPO to advance its pipeline of immuno-oncology therapies. More

> Martin Shkreli, the controversial CEO of Turing Pharmaceuticals, made a $2,700 donation to Sen. Bernie Sanders' presidential effort, a gift the campaign said it will donate to charity. Story

Medical Device News

@FierceMedDev: Check out this year's Fierce 15: The new strategic med tech mania sets the stage for 2015's Fierce 15. Feature | Follow @FierceMedDev

@VarunSaxena2: #TCT15: Startup's minimally invasive mitral valve repair tech shows promise in feasibility study. Article | Follow @VarunSaxena2

@EmilyWFierce: ICYMI: 23andMe adds chapter to comeback story with $115M in funding. Report | Follow @EmilyWFierce

> Theranos dials down lab testing amid FDA pushback. Story

> WSJ: Former Theranos employees reveal problems with proprietary testing device. More

Pharma News

@FiercePharma: India pharma sees trouble for its industry in newly negotiated TPP. More | Follow @FiercePharma

@EricPFierce: Pests, lack of data integrity thwart another Indian API maker, this time Unimark Remedies. News | Follow @EricPFierce

@CarlyHFierce: After FDA snub, AZ diabetes combo faces potential years-long delay. Article | Follow @CarlyHFierce

> U.K. cost watchdog gives thumbs-up to Bristol-Myers' hep C drug. Story

> FDA's review of BI's Pradaxa was 'lax' and 'permissive,' watchdog claims. Article

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.